Report Phase 3 maintenance study results and make regulatory submissions for Rinvoq in ulcerative colitis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Apr 2021
- Due
- 31 Dec 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Results from the Phase 3 maintenance study and regulatory submissions are expected in 2H 2021.”
What we found
Evidence strength A What the grades mean
AbbVie reported Phase 3 maintenance study results in June 2021 and made regulatory submissions for Rinvoq in ulcerative colitis in September 2021, both within the 2H 2021 deadline.
-
A AbbVie Inc. 10-K filed 2022-02-18
“In June 2021, AbbVie announced the results from its Phase 3 maintenance study of Rinvoq in patients with UC met the primary and all secondary endpoints.” ✓ confirmed on the page
-
A AbbVie Inc. 10-K filed 2022-02-18
“In September 2021, AbbVie submitted an sNDA to the FDA and an MAA to the EMA for Rinvoq for the treatment of adults with moderately to severely active UC.” ✓ confirmed on the page
Market reaction: the shares moved +4.7% against the S&P 500 over the three sessions around the disclosure (17 Feb 2022 to 23 Feb 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 maintenance study results and regulatory submissions
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you AbbVie Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ABBV-004139 · Corrections policy